Personal and professional impact of COVID-19

Thursday, July 9, 2020

Oncologist Don S. Dizon, MD, joins the podcast to discuss how the COVID-19 pandemic has affected him personally and professionally. Dr. Dizon is the director of women’s cancers at Lifespan Cancer Institute and director of medical oncology at Rhode Island Hospital, both in Providence.

Dr. Dizon tells host David H. Henry, MD, how COVID-19 affected his patients, colleagues, and research as well as his personal life. Dr. Dizon chronicled some of these developments in a series of columns published on Medscape.

Disclosures:

Dr. Dizon has relationships with Regeneron, Astra-Zeneca, Clovis, Bristol-Myers Squibb, and Kazia. He is a columnist for Medscape, which is owned by the same parent company as MDedge News.

Dr. Henry has no relevant disclosures.

* * *

For more MDedge Podcasts, go to mdedge.com/podcasts

Email the show: podcasts@mdedge.com

Interact with us on Twitter: @MDedgehemonc

David Henry on Twitter: @davidhenrymd

How to Listen

Podcast Participants

David Henry, MD
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.



More Episodes from Blood & Cancer

View All Episodes

Close